Register for email alerts and news feeds:
This journal | BMJ Group
rss
Journal of Clinical Pathology 2005;58:762-765; doi:10.1136/jcp.2004.024331
Copyright © 2005 by the BMJ Publishing Group Ltd & Association of Clinical Pathologists.
Journal of Clinical Pathology 2005;58:762-765
© 2005 BMJ Publishing Group Ltd & Association of Clinical Pathologists

ORIGINAL ARTICLE

No GIST-type c-kit gain of function mutations in neuroblastic tumours

M Korja1, J Finne1, T T Salmi2, H Haapasalo3, M Tanner5 and J Isola4

1 Department of Medical Biochemistry and Molecular Biology, University of Turku, Kiinamyllynkatu 10, FI-20520 Turku, Finland
2 Department of Paediatrics, Turku University Central Hospital, Turku, FI-20520 Finland
3 Department of Pathology, Tampere University Hospital, FI-33521 Tampere, Finland
4 Laboratory of Cancer Biology, Institute of Medical Technology, University of Tampere and Tampere University Hospital, FI-33014 Tampere, Finland
5 Department of Oncology, Tampere University Hospital, FI-33520

Correspondence to:
Correspondence to:
Dr M Korja
Department of Medical Biochemistry and Molecular Biology, University of Turku, Kiinamyllynkatu 10, FI-20520 Turku, Finland; miikka.korja{at}utu.fi

Aims: Neuroblastic tumours (NTs) have been shown to respond to imatinib treatment in vivo and in vitro, possibly via inactivating the c-kit receptor. The purpose of this study was to identify gastrointestinal stromal tumour (GIST)-type c-kit gene associated mutations in exons 9, 11, 13, and 17 in NTs to recognise a subset of tumours that would probably respond to imatinib treatment.

Methods: Expression of the c-kit protein was detected immunohistochemically in a total of 37 archival paraffin wax embedded NTs using polyclonal rabbit antihuman c-kit antibody. After immunohistochemistry, c-kit gene associated chromosomal mutations in all cases of NT were detected with denaturing high performance liquid chromatography (HPLC).

Results: Denaturing HLPC analysis did not reveal GIST-type mutations in four immunohistochemically detected c-kit positive or in 33 c-kit negative NTs.

Conclusions: c-kit receptor expression and GIST-type c-kit gene mutations are rare events in NTs. Oncogenic activation of c-kit in NTs presumably differs from that of GISTs, which may influence their responsiveness to imatinib treatment. Whether c-kit has an essential role in the pathogenesis of NTs remains to be investigated.

Abbreviations: GIST, gastrointestinal stromal tumour; HPLC, high performance liquid chromatography; NT, neuroblastic tumour; PCR, polymerase chain reaction

Keywords: c-kit; gastrointestinal stromal tumour; neuroblastoma; neuroblastic; imatinib


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Pathology jobs

Pathology jobs